Headlines about Bristol-Myers Squibb (NYSE:BMY) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.385220113195 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the media stories that may have impacted Accern’s rankings:
- Bristol-Myers Squibb Company (BMY) Shows Effort to Maintain Active Position in Short-Range Commitments – Stock News Stop (stockmarketstop.com)
- Bristol-Myers Squibb Company (BMY) – Traders Alert on Unusual Volume Activity – Wall Street Morning (wallstreetmorning.com)
- Bristol-Myers Squibb’s (BMY) 36th Annual JP Morgan Healthcare Brokers Conference (Transcript) – Seeking Alpha (seekingalpha.com)
- What to Expect from Roche’s Investigational Drug Polatuzumab Vedotin (finance.yahoo.com)
- Bristol-Myers Squibb Co (BMY) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
Bristol-Myers Squibb (BMY) traded up $0.46 during mid-day trading on Thursday, hitting $62.47. The stock had a trading volume of 5,066,489 shares, compared to its average volume of 5,460,000. Bristol-Myers Squibb has a 12-month low of $46.01 and a 12-month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The stock has a market cap of $102,240.00, a PE ratio of 24.59, a P/E/G ratio of 2.22 and a beta of 1.18.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is presently 62.99%.
Several research analysts have issued reports on the company. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price on the stock. in a research report on Thursday, December 28th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Monday, December 11th. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Tuesday, December 5th. Finally, SunTrust Banks raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $65.05.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This article was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.com-unik.info/2018/01/11/bristol-myers-squibb-bmy-earning-somewhat-positive-media-coverage-analysis-shows.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.